A RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA AFTER 1ST RECURRENCE: A REPORT FROM THE JAPAN NEUROBLASTOMA STUDY GROUP

被引：0
|
作者：
Hara, Junichi [1 ]
Takimoto, Tetsuya [2 ]
Shichino, Hiroyuki [3 ]
Matsumoto, Kimikazu [4 ]
Kuroda, Tatsuo [5 ]
Hishiki, Tomoro [6 ]
Soejima, Toshinori [7 ]
Hashii, Yoshiko [8 ]
Mori, Tetsuya [9 ]
Ikeda, Hitoshi [10 ]
机构：
[1] Osaka City Gen Hosp, Osaka, Japan
[2] Natl Ctr Child Hlth & Dev, Tokyo, Japan
[3] Nihon Univ, Tokyo, Japan
[4] Japanese Red Cross Nagoya First Hosp, Nagoya, Aichi, Japan
[5] Keio Univ, Tokyo, Japan
[6] Chiba Univ, Grad Sch Med, Chiba, Japan
[7] Hyogo Prefectural Canc Ctr, Akashi, Hyogo, Japan
[8] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan
[9] Natl Ctr Child Hlth & Dev, Tokyo, Japan
[10] Dokkyo Med Univ, Koshigaya Hosp, Koshigaya, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2012年 / 59卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1059 / 1059
页数：1
相关论文
共 50 条
  • [31] Evaluation of patients with advanced neuroblastoma surviving more than 5 years after initiation of an intensive Japanese protocol: A report from the study group of Japan for treatment of advanced neuroblastoma
    Iwafuchi, M
    Utsumi, J
    Tsuchida, Y
    Kaneko, M
    Matsuyama, S
    Ohnuma, N
    Taguchi, N
    Mugishima, H
    Yokoyama, J
    Sasaki, S
    Yoshioka, A
    Nagahara, N
    Fukuzawa, M
    Suita, S
    MEDICAL AND PEDIATRIC ONCOLOGY, 1996, 27 (06): : 515 - 520
  • [32] INDICATION AND LIMITS OF MEGATHERAPY AND BONE-MARROW TRANSPLANTATION IN HIGH-RISK NEUROBLASTOMA - A SINGLE CENTER ANALYSIS OF PROGNOSTIC FACTORS
    LADENSTEIN, R
    FAVROT, M
    LASSET, C
    BOUFFET, E
    PHILIP, I
    COMBARET, V
    CHAUVIN, F
    BRUNATMENTIGNY, M
    BIRON, P
    PHILIP, T
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (07) : 947 - 956
  • [33] Roles of Surgery in the Treatment of Patients With High-Risk Neuroblastoma in the Children Oncology Group Study: A Systematic Review and Meta-Analysis
    Qi, Yingyi
    Zhan, Jianghua
    FRONTIERS IN PEDIATRICS, 2021, 9
  • [34] Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales-A report from the Children's Oncology Group (COG).
    Landier, W.
    Knight, K. R.
    Wong, F. L.
    Lee, J. K.
    Thomas, O.
    Kim, H.
    Kreissman, S. G.
    Schmidt, M. L.
    Chen, L.
    London, W. B.
    Bhatia, S.
    Gurney, J. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Risk factors in stage 4 neuroblastoma patients treated with Busulphan-Melphalan. Report from the European High Risk Neuroblastoma HR-NBL1/SIOPEN TRIAL
    Ladenstein, R.
    Poetschger, U.
    Elliot, M.
    Luksch, R.
    Castel, V.
    Yaniv, I.
    Papadakis, V.
    Laureys, G.
    Malis, J.
    Balwierz, W.
    Ruud, E.
    Kogner, P.
    Schroeder, H.
    de lacerda, A. Forjaz
    Beck-Popovic, M.
    Bician, P.
    Garami, M.
    Trahair, T.
    Ambros, P.
    Holmes, K.
    Schreier, G.
    Gaze, M.
    Pearson, A.
    Valteau-Couanet, D.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S46 - S46
  • [36] Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children's Cancer Group Neuroblastoma Committee (JCCG-JNBSG)
    Ohira, Miki
    Nakamura, Yohko
    Takimoto, Tetsuya
    Nakazawa, Atsuko
    Hishiki, Tomoro
    Matsumoto, Kimikazu
    Shichino, Hiroyuki
    Iehara, Tomoko
    Nagase, Hiroki
    Fukushima, Takashi
    Yoneda, Akihiro
    Tajiri, Tatsuro
    Nakagawara, Akira
    Kamijo, Takehiko
    BIOMOLECULES, 2022, 12 (01)
  • [37] Influence of image-defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group
    Monclair, Tom
    Mosseri, Veronique
    Cecchetto, Giovanni
    De Bernardi, Bruno
    Michon, Jean
    Holmes, Keith
    PEDIATRIC BLOOD & CANCER, 2015, 62 (09) : 1536 - 1542
  • [38] Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study
    Braunstein, Steve E.
    London, Wendy B.
    Kreissman, Susan G.
    Villablanca, Judith G.
    Davidoff, Andrew M.
    DeSantes, Kenneth
    Castleberry, Robert P.
    Murray, Kevin
    Diller, Lisa
    Matthay, Katherine
    Cohn, Susan L.
    Shulkin, Barry
    von Allmen, Daniel
    Parisi, Marguerite T.
    Van Ryn, Collin
    Park, Julie R.
    La Quaglia, Michael P.
    Haas-Kogan, Daphne A.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (07)
  • [39] Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project
    Moroz, Veronica
    Machin, David
    Faldum, Andreas
    Hero, Barbara
    Iehara, Tomoko
    Mosseri, Veronique
    Ladenstein, Ruth
    De Bernardi, Bruno
    Rubie, Herve
    Berthold, Frank
    Matthay, Katherine K.
    Monclair, Tom
    Ambros, Peter F.
    Pearson, Andrew D. J.
    Cohn, Susan L.
    London, Wendy B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (04) : 561 - 571
  • [40] ASSOCIATION OF HIGH CERAMIDE LEVELS WITH UNFAVORABLE NEUROBLASTOMA RISK FACTORS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
    Escoto, Heather
    London, Wendy B.
    McGrady, Patrick W.
    Kraveka, Jacqueline M.
    PEDIATRIC BLOOD & CANCER, 2009, 52 (06) : 733 - 733
12345